Generate Biomedicines Inc... (GENB)

NasdaqGS: GENB · Real-Time Price · USD

16.14

-4.24 (-20.80%)

At close: Aug 27, 2026, 3:59 PM

15.80

+0.19%

After-hours: 7:43 PM

The price, the headline numbers and the latest news, in one place.

-20.80% (1D)

Bid	14.19
Market Cap	2.02B
Revenue (ttm)	26.48M
Net Income (ttm)	-268.67M
	n/a
	-2.09
	n/a
	-6.92
P/B (ttm)	4.44
P/S (ttm)	76.43
Earnings Date	Nov 5, 2026

Ask	20.42
Volume	3,835,199
Avg. Volume (20D)	944,868
Open	19.80
Previous Close	20.38
Day's Range	15.93 - 20.14
52-Week Range	11.00 - 22.67
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About GENB

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 27, 2026

Employees 312

Stock Exchange NasdaqGS

Ticker Symbol GENB

Website https://generatebiomedicines.com

Full Company Profile

Financial Performance

In 2025, Generate Biomedicines's revenue was 31.89M, an increase of 55.89% compared to the previous year's 20.46M. Earnings were -203.15M, an increase of 16.91%.

Financial Statements

Earnings Surprise

Generate Biomedicines has released their quarterly earnings on Aug 6, 2026:

Revenue of $6.31M misses estimates by $0, with Infinity% YoY growth.
EPS of -0.52 misses estimates by -0.02, with -Infinity% YoY decline.

Next Earnings Release

Generate Biomedicines Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 day ago · Simply Wall St.

Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns

Generate Biomedicines has delivered a 27.6% gain year to date, yet on broad valuation checks the stock screens as expensive rather than a clear bargain. With the post IPO lock up expiration drawing at...

2 days ago · Proactive

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wedn...